Covid: Valneva launches the request for authorization of its vaccine in the United Kingdom – archyde

The Franco-Austrian laboratory Valneva announced on Monday that it had started the gradual submission of its request for authorization of its candidate vaccine against Covid-19 to the British health authorities.

The laboratory’s phase 3 trials, intended to prove the real effectiveness of a treatment before it is eventually put on the market, are still ongoing.

He hopes “that an initial authorization could be granted to it by the end of 2021” for the placing on the market.

Valneva has already signed a contract with the United Kingdom to deliver this vaccine in the event of a positive test.

The first part of the phase 3 trials is taking place in the United Kingdom, but Valneva began in early August “a complementary trial” in New Zealand, with people over 56 years.

The laboratory uses a deactivated virus vaccine, a technology more traditional than those of vaccines currently approved in the European Union: Pfizer-BioNTech and Moderna, which are messenger RNA, and AstraZeneca and Johnson & Johnson, which work by viral vector.

fs / pn / spi